We were selected from many applicants and received the award at NIPPON INNOVATION TRYOUT 2025.
Setolabo LLC’s technology for ultra-early detection of 16 types of cancer with miRNA from a single blood draw and its vision to expand this technology globally were highly evaluated, and we were awarded 30 million yen in research and development support.
We would like to express our sincere gratitude to everyone who supports us. We will continue to take on the challenge of realizing early cancer detection!